Drager sales up 3.7%:
This article was originally published in Clinica
Executive Summary
Medtech revenues contributed some 65% of German company Drager's total sales of DM 1,435 million ($1,000 million) in 1995, which were up 3.7% on the previous year. When expressed in local currencies this represents growth of 8%. Medical technology sales increased around 4% in Germany and about 13% abroad. Group net profits were DM 13.7 million, down nearly 10% on 1994. The company blames high German production costs and currency effects. The company spent DM 106 million on R&D, compared with DM 93.5 million in 1994. Drager TGM, which will expand the company's equipment servicing programme for hospitals, was set up in Kirchheimbolanden, Germany, at the end of May.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.